Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company OncoTherapy Science Inc.
Description mAb that selectively binds to pathological aggregates of beta amyloid peptide
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerKyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today